Voyager Therapeutics Reports Q1 2026 Results, Extends Cash Runway into 2028, and Advances Key Pipeline Programs

summarizeSummary

Voyager Therapeutics reported a reduced net loss in Q1 2026 due to cost-cutting, extending its cash runway into 2028, and announced positive pipeline advancements despite a decline in collaboration revenue and partial termination of some Novartis programs.

check_boxKey Events

• Reduced Net Loss and Operating Expenses

  Voyager Therapeutics reported a net loss of $27.9 million for Q1 2026, an improvement from $31.0 million in Q1 2025. Total operating expenses decreased by $8.3 million to $32.9 million, driven by cost-cutting and program prioritization, including the discontinuation of the SOD1 program.

• Extended Cash Runway into 2028

  The company's cash, cash equivalents, and marketable securities totaled $171.7 million as of March 31, 2026, which is expected to be sufficient to fund planned operating expenses and capital expenditures into 2028.

• Pipeline Advancement for Alzheimer's and Friedreich's Ataxia Programs

  The VY1706 gene therapy program for Alzheimer's disease is on track for IND application completion in Q2 2026 and clinical trial initiation in H2 2026. The Neurocrine FA Program (NBIB-223) received FDA Orphan Drug Designation in May 2026, with a clinical trial expected to start in H2 2026.

• Partial Termination of Novartis Collaboration Programs

  Novartis partially terminated two programs under the 2022 Option and License Agreement, effective February 1, 2026, resulting in the loss of potential future milestone payments and royalties for those specific targets.

auto_awesomeAnalysis

Voyager Therapeutics, Inc. reported a net loss of $27.9 million for Q1 2026, an improvement from the $31.0 million loss in Q1 2025, primarily driven by significant reductions in operating expenses. The company successfully decreased total operating expenses to $32.9 million from $41.2 million year-over-year, reflecting continued portfolio prioritization and cost-cutting initiatives, including the discontinuation of the SOD1 program and reduced spending on the anti-tau antibody program (VY7523). Despite a decrease in collaboration revenue from $6.5 million to $2.6 million, the company's cash, cash equivalents, and marketable securities of $171.7 million as of March 31, 2026, are projected to fund operations into 2028. This extended cash runway is a critical positive for a biotechnology company. The company also reported progress on its pipeline, with the VY1706 gene therapy program for Alzheimer's disease anticipating IND application completion in Q2 2026 and clinical trial initiation in H2 2026. Additionally, the Neurocrine FA Program (NBIB-223) received Orphan Drug Designation from the FDA in May 2026, with a clinical trial expected to start in H2 2026. While Novartis partially terminated two programs under a 2022 agreement, Voyager retains other active collaborations and its proprietary pipeline continues to advance. The company also raised $3.0 million in net proceeds through its At-The-Market (ATM) facility, with $96.9 million remaining available, following the recent proposal to double authorized common stock.